Key result
Mexiletine serves as first-line LQT3 treatment and may stabilize refractory ventricular tachyarrhythmias and electrical storms.
Why the study?
New European Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death were recently published, reappraising established older antiarrhythmic drugs including mexiletine.
Mexiletine is highlighted in recent ESC guidelines as a first-line therapy for LQT3 and shows promise as an adjunctive treatment for refractory ventricular arrhythmias.
May guide mexiletine use in refractory LQT3; leaves open prospective validation beyond current guidelines.
INTRODUCTION: Mexiletine is a class IB sodium-channel blocker. Unlike class IA or IC antiarrhythmic drugs, mexiletine rather shortens than prolongs action potential duration; therefore, it is less associated with proarrhythmic effects. AREAS COVERED: Recently, new European Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death were published, including a reappraisal of some established older antiarrhythmic drugs. EXPERT OPINION: Mexiletine offers a first-line, genotype-specific treatment strategy for LQT3 patients as emphasized by the most recent guidelines. Besides this recommendation, current study reports suggest that in therapy-refractory ventricular tachyarrhythmias and electrical storms adjunctive mexiletine treatment may offer the possibility of stabilizing patients with or without concomitant interventional therapy such as catheter ablation.
No takes yet. Share an insight, caveat, or question.
Vámos et al. (2023) conducted a review in Ventricular arrhythmias and LQT3. Mexiletine was evaluated. Mexiletine serves as a first-line, genotype-specific treatment for LQT3 patients and may stabilize those with therapy-refractory ventricular tachyarrhythmias and electrical storms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: